• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Biota and Nabi merge to form Biota Pharmaceuticals

Biota and Nabi merge to form Biota Pharmaceuticals

April 23, 2012
CenterWatch Staff

Biota Holdings, an Australian anti-infective drug development company, and Nabi Biopharmaceuticals of Rockville, Md., have signed a Merger Implementation Agreement to form the combined company Biota Pharmaceuticals, to be headquartered in the U.S.

Biota Holdings’ move to the U.S. is designed to achieve better value recognition and liquidity through a stronger U.S. shareholder base. Following the merger, Biota Pharmaceuticals will have three royalty generating products, Relenza, Inavir and potentially PhosLyra; a $231 million contract with BARDA for the advanced development of laninamivir; a portfolio of clinical and pre-clinical programs comprising vapendavir (HRV), and programs for respiratory syncytial virus (RSV), hepatitis C (HCV-NN), broad spectrum antibiotic targeting gyrase (GYR); an interest in NicVAX; and over $100 million in cash.

Through the merger, Nabi will acquire all shares in BTA for new shares in the name of Biota Pharmaceuticals. After the completion of the merger, current Biota Holdings shareholders will own approximately 74% of Biota Pharmaceuticals and Nabi shareholders will own approximately 26% of Biota Pharmaceuticals.

Furthermore, Nabi’s assets at merger will include $54 million in cash, a right to receive royalties from a marketed product (PhosLyra) and an interest in NicVAX. After satisfying certain obligations, Nabi plans to return the $54 million in cash to its existing shareholders cash, since the amount is simply required to be held by Nabi at closing. Nabi also intends to distribute contingent value rights providing payout rights from future sale, transfer, license or similar transactions involving NicVAX.

The board of directors of the new Biota Pharmaceuticals will consist of six former Biota Holdings directors, including the chairman, and two former Nabi directors. Biota Holdings’ current CEO and CFO will continue in their roles.

The merger will require approval from both Biota Holdings and Nabi shareholders and independent reports confirming that the merger will be in the best interest of the shareholders. The Merger Implementation Agreement notes several other conditions, as well.

The companies expect the transaction to close by September 30, 2012, after satisfaction of customary closing conditions and regulatory approvals.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing